Detalles de la búsqueda
1.
TES and SLC40A1 as potential biomarkers for predicting survival in T-cell acute lymphoblastic leukemia.
Acta Haematol;
2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38806013
2.
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN.
Haematologica;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695123
3.
Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Clin Transl Sci;
17(1): e13711, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129985
4.
Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms.
Hematology;
28(1): 2288475, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38038045
5.
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
BMC Cancer;
23(1): 980, 2023 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37838670
6.
Stem cell-based therapy for COVID-19.
Int Immunopharmacol;
124(Pt A): 110890, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37688914
7.
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
Am J Hematol;
98(9): 1407-1414, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37421604
8.
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Am J Hematol;
98(7): E183-E186, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37128776
9.
Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-ß-SMAD2/3 pathway.
Mol Med;
29(1): 59, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37098464
10.
Validation of the imatinib-therapy failure model.
Leukemia;
37(5): 1166-1169, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36973351
11.
Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML.
Clin Transl Oncol;
25(6): 1805-1820, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36899123
12.
Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
Front Immunol;
14: 1078118, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36742315
13.
Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Int Immunopharmacol;
117: 109746, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36827923
14.
Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia.
Front Oncol;
12: 1057153, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36408189
15.
The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance.
Front Microbiol;
13: 813576, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36160244
16.
Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma.
Front Cardiovasc Med;
9: 994384, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119749
17.
Mutant C/EBPα p30 alleviates immunosuppression of CD8+ T cells by inhibiting autophagy-associated secretion of IL-1ß in AML.
Cell Prolif;
55(12): e13331, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36124714
18.
Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Front Immunol;
13: 950134, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36003379
19.
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.
J Hematol Oncol;
15(1): 68, 2022 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35597971
20.
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
BMC Med;
20(1): 108, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35379237